Business
Cereno Scientific to Attend JPM Week and Biotech Showcase in San Francisco, US, on January 12-18, 2026
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will attend JPM Week 2026 and participate at the Biotech Showcase in San Fransisco, US, on January 12-18, 2026
About this update from Cereno Scientific Ab Class B
[{"type":"text","content":"GOTHENBURG, Sweden, Dec. 12, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will attend JPM Week 2026 and participate at the Biotech Showcase in San Fransisco, US, on January 12-18, 2026","length":372,"tagName":"p"},{"type":"text","content":"The JPM Week is the largest annual gathering for global life science stakeholders, bringing together biotechnology and pharmaceutical companies, investors, analysts, patient advocacy groups, and industry experts. In parallel with the main J.P. Morgan Healthcare Conference, a broad set of satellite events, partner meetings, and scientific and corporate presentations take place across the city, creating a hub for strategic dialogue, collaboration, and innovation.","length":465,"tagName":"p"},{"type":"text","content":"Cereno Scientific will participate in meetings throughout the week and will also be present at the Biotech Showcase, an investor and partnering event, on January 12-14, running concurrently with J.P. Morgan's conference activities.","length":235,"tagName":"p"},{"type":"text","content":""Our participation in JPM Week marks an important moment each year as we engage with the global biotech and pharma community at one of the industry's most influential gatherings," said Sten R. Sörensen, CEO of Cereno Scientific. "Over the past year, we have achieved meaningful progress across our pioneering HDAC inhibitor portfolio. Sharing this momentum, including the advancement of our lead candidate CS1 toward a global Phase IIb trial in PAH and the strong Phase I data supporting CS014's progression into Phase II has already generated increasing interest from potential partners, investors, and scientific leaders. We look forward to a highly productive week of discussions as we continue to build strategic relationships and explore opportunities that support our mission to bring disease-modifying treatments to patients with rare cardiovascular and pulmonary diseases."","length":909,"tagName":"p"},{"type":"text","content":"To book a meeting with Cereno Scientific, please contact: [email protected], or connect with the team via the Biotech Showcase partnering pla...